EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)VergleichsstudieOpen access · CC BY-NC-ND 4.0

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults

Susan Bodie, Aidan K Curran, Aaron C Gonzalez-Nelson, Jason M Perry, Debora C Manning, Margaret M Wasilewski

Headache: The Journal of Head and Face Pain · 2024

DOI: 10.1111/head.14731 ↗

At a glance

Randomisierte kontrollierte Studie in Headache: The Journal of Head and Face Pain, 2024. Written by Susan Bodie and 5 co-authors. Institution: Pulmatrix Inc., Bedford, Massachusetts, USA. Major MEDLINE topics: Dihydroergotamine, Administration, Intravenous. Cited 1 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Pulmatrix Inc..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Intravenous dihydroergotamine (DHE) has well‐established efficacy for the acute treatment of migraine, but its use is limited by the need for in‐hospital administration and the nausea/vomiting associated with a high maximum plasma concentration (C max ). Inhalation is an alternative to intravenous dosing. The surface area of the lung allows for rapid absorption of a self‐administered dose.

Objective

This study evaluated the safety, tolerability, and systemic pharmacokinetics (PK) of a dry powder formulation (PUR3100) DHE when delivered via inhalation compared to intravenous delivery. Method s In this double‐blind, double‐dummy Phase 1 study, healthy volunteers ( N = 26) were randomized (1:1:1:1) to one of four groups: orally inhaled placebo plus intravenous DHE 1.0 mg or orally inhaled PUR3100 (0.5, 1.0, or 1.5 mg) plus intravenous placebo. Blood samples were drawn pre‐dose and at time points post‐dose over 48 h. Standard PK and safety parameters were assessed and values for C max and area under plasma concentration time curve (AUC) were used to assess comparative exposures of PUR3100 versus intravenous DHE.

Results

All doses of PUR3100 were associated with a lower incidence of nausea (21% vs. 86%), vomiting (0% vs. 29%), and headache (16% vs. 57%) compared to intravenous DHE. The PK profile of PUR3100 versus intravenous DHE was characterized by a similar mean time to C max (5 vs. 5.5 min), with reduced AUC 0–2h (1120–4320 vs. 6340), and a lower C max (3620–14,400 vs. 45,000). Compared to intravenous DHE 1.0 mg, the highest nominal PUR3100 dose (1.5 mg), which delivers a fine‐particle dose of approximately 0.9 mg to the lungs, had a geometric mean ratio percentage (90% confidence interval [CI]) for C max of 32% [17.2, 59.6] and AUC 0–inf of 93% (62.9, 138.5), the latter of which was not significantly different.

Conclusions

Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and an improved safety profile relative to intravenous DHE.

Subjects

MeSH terms (MEDLINE)

DihydroergotamineAdministration, IntravenousHumansDouble-Blind MethodMaleAdultFemaleAdministration, InhalationYoung AdultHealthy VolunteersMiddle AgedDry Powder InhalersAdolescent

Author keywords

acute migrainedihydroergotamineinhalationpharmacokineticssafety

Substances

Dihydroergotamine

Authors and institutions

  • Pulmatrix Inc., Bedford, Massachusetts, USA.
  • Veristat, Southborough, Massachusetts, USA.

Funding

  • Pulmatrix Inc.

Cite

APA

Bodie, S., Curran, A. K., Gonzalez-Nelson, A. C., Perry, J. M., Manning, D. C., & Wasilewski, M. M. (2024). Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14731

Vancouver

Bodie S, Curran AK, Gonzalez-Nelson AC, Perry JM, Manning DC, Wasilewski MM. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14731

BibTeX
@article{Bodie2024,
  author = {Bodie, Susan and Curran, Aidan K and Gonzalez-Nelson, Aaron C and Perry, Jason M and Manning, Debora C and Wasilewski, Margaret M},
  title = {Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  doi = {10.1111/head.14731}
}
Start for free →